Other anticoagulants

Contributing journals to this collection:
Hypertension, Circulation: Heart Failure, Stroke, Circulation Research, Circulation: Arrhythmia and Electrophysiology, Circulation: Cardiovascular Genetics, Arteriosclerosis, Thrombosis, and Vascular Biology, Circulation: Cardiovascular Outcomes and Quality, Circulation, Circulation: Cardiovascular Interventions, and Circulation: Cardiovascular Imaging

Citations 1-10 of 163 total displayed.

Most recent content

Original Contributions
Ancrod in Acute Ischemic Stroke: Results of 500 Subjects Beginning Treatment Within 6 Hours of Stroke Onset in the Ancrod Stroke Program

David E. Levy, Gregory J. del Zoppo, Bart M. Demaerschalk, Andrew M. Demchuk, Hans-Christoph Diener, George Howard, Markku Kaste, Arthur M. Pancioli, Carmen Spatareanu, and Warren W. Wasiewski
Stroke 2009;40:3796-3803; published online before print as doi:10.1161/STROKEAHA.109.565119 [Abstract] [Full text]  

Past content

Correspondence
Response to Letter Regarding Article, "Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial"

Barry M. Massie, Susan E. Ammon, Joseph F. Collins, William F. Krol, Paul W. Armstrong, John G.F. Cleland, Michael Ezekowitz, Syed M. Jafri, Christopher M. O'Connor, Kevin A. Schulman, Koon Teo, and Stuart Warren
Circulation 2009;120:e165, doi:10.1161/CIRCULATIONAHA.109.884650 [Full text]  

Vascular Medicine
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials

John W. Eikelboom, Daniel J. Quinlan, and Martin O'Donnell
Circulation 2009;120:2006-2011; published online before print as doi:10.1161/CIRCULATIONAHA.109.872630 [Abstract] [Full text]  

Articles
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials

John W. Eikelboom, Daniel J. Quinlan, and Martin O'Donnell
Circulation published November 2, 2009, doi:10.1161/CIRCULATIONAHA.109.872630 [Abstract]  

Articles
Ancrod in Acute Ischemic Stroke. Results of 500 Subjects Beginning Treatment Within 6 Hours of Stroke Onset in the Ancrod Stroke Program

David E. Levy, Gregory J. del Zoppo, Bart M. Demaerschalk, Andrew M. Demchuk, Hans-Christoph Diener, George Howard, Markku Kaste, Arthur M. Pancioli, Carmen Spatareanu, and Warren W. Wasiewski
Stroke published October 29, 2009, doi:10.1161/STROKEAHA.109.565119 [Abstract]  

Editorials
New Therapies for Stroke Prevention in Atrial Fibrillation: The Long Road to Enhanced Efficacy

Jane E. Freedman and Bernard J. Gersh
Circulation 2009;120:1024-1026; published online before print as doi:10.1161/CIRCULATIONAHA.109.893362 [Full text]  

Arrhythmia/Electrophysiology
The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation

David J. Ellis, Mohammed Haris Usman, Peter G. Milner, Daniel M. Canafax, and Michael D. Ezekowitz
Circulation 2009;120:1029-1035; published online before print as doi:10.1161/CIRCULATIONAHA.109.856120 [Abstract] [Full text]  

Articles
New Therapies for Stroke Prevention in Atrial Fibrillation. The Long Road to Enhanced Efficacy

Jane E. Freedman and Bernard J. Gersh
Circulation published September 9, 2009, doi:10.1161/CIRCULATIONAHA.109.893362 [Abstract]  

Articles
New Therapies for Stoke Prevention in Atrial Fibrillation. The Long Road to Enhanced Efficacy

Jane E. Freedman and Bernard J. Gersh
Circulation published September 8, 2009, doi:10.1161/CIRCULATIONAHA.109.893362 [Abstract]  

Articles
The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation

David J. Ellis, Mohammed Haris Usman, Peter G. Milner, Daniel M. Canafax, and Michael D. Ezekowitz
Circulation published September 8, 2009, doi:10.1161/CIRCULATIONAHA.109.856120 [Abstract]  

[Next page] Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17